
    
      This study is designed to evaluate the therapeutic effects and safety of oral ALK4290
      administered at 800 mg daily over a 6-week dosing period in newly diagnosed (treatment na√Øve)
      patients with wAMD. The study agent will be orally self-administered. All subjects will
      receive the study agent, ALK4290. This study does not contain a placebo.
    
  